Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
Wente
Moritz N
MN
Department of General Surgery, Ruprecht-Karls-University, Heidelberg, Heidelberg, Germany.
Sauer
Peter
P
Mehrabi
Arianeb
A
Weitz
Jürgen
J
Büchler
Markus W
MW
Schmidt
Jan
J
Schemmer
Peter
P
D003692:Delayed-Action Preparations; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D016559:Tacrolimus / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D016559:Tacrolimus